Furthermore, the combination of TA99 with anti-4-1BB mAb also resulted in a significant reduction in tumor size when treatment was started after the subcutaneous B16 tumors reached a volume between 65 and 80 mm3 (Figure 2C). The gene discussed is TNFRSF9; the disease is neoplasm.